Abstract
Wilson discusses a study conducted by Timothy Powell at King's College London which showed that genetics may account for up to 42 per cent of the variation in the likelihood of getting infected. These findings could help in the development of new treatments or vaccines against HIV. Powell and his team reanalyzed the data from this 2013 study and found many other genetic variants that play a role. They also looked at a separate large study of health and genes and found that high genetic risk of HIV infection was linked to lower blood levels of a molecule called CCL17, which is involved in signalling between immune cells. If confirmed, this suggests vaccine developers could focus on people with low CCL17 when developing their products.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
